Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (844)	5/21/1998 10:14:00 AM
From: yosi s	Read Replies (2) of 1491

Nice information. I also like that PARS is giving information, on studies that are in very early phases of development. This is nice ot see that the information is presented in a national forum. HU 211 by its mechanisme of action may find very broad indication for future use. Indeed this may give the company significant support to find a major partner. and to set up for larger future indication. The larger the potential market the more a big pharmaceutical partner will find this "gem" to be attractive, the bigger the upside potential. I also like the fact that in animal studies inflamation was done and apetite stimulated. This is important and very relevent information. Hopefully human studies will follow soon.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next